Answers are grounded in this paper and cite their sources.
Receptor tyrosine kinases (RTKs) play a major role in tumor growth, survival, angiogenesis, and drug resistance, making them important targets in anticancer therapy. The present work aimed to rationally design novel piperazine–oxadiazole-appended imidazo[2,1- b ][1,3,4]thiadiazoles capable of targeting receptor tyrosine kinases EGFR (3POZ), VEGFR2 (1YWN), and HER2 (3PP0) through a molecular hybridization strategy. Thirty novel piperazine-oxadiazole appended imidazo[2,1- b ][1,3,4]-thiadiazole derivatives were designed and evaluated in silico against Epidermal Growth Factor Receptor (EGFR), Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Human Epidermal Growth Factor Receptor 2 (HER2). Molecular docking studies showed favorable binding affinities for most of the compounds toward the selected receptors. Compound P5 and P9 exhibited the best docking profiles with significant interactions at the active sites. ADMET and physicochemical analyses indicated that most of the derivatives satisfied Lipinski’s rule of five and possessed promising drug-like properties. Molecular dynamics simulations at 100 ns confirmed the stability of P5 and P9 complexes through stable RMSD, RMSF, radius of gyration (Rg), and solvent-accessible surface area (SASA) profiles. Free energy landscape (FEL) and MM-PBSA analyses further supported favorable binding stability and binding energies. These findings suggest that compound P9 may serve as promising lead candidates for further experimental validation where as compound P5 emerged as binding-oriented computational candidate requiring further structural optimization. Although entirely computational, the present study provides a rational framework for future synthesis and biological evaluation.
No takes yet. Share an insight, caveat, or question.
Govindaiah et al. (2026) studied this question.